Rakuten Investment Management Inc. Buys New Position in IQVIA Holdings Inc. $IQV

Key Points

• Rakuten Investment Management bought 27,459 IQVIA shares worth approximately $5.3 million in the second quarter. Institutional investors now own 89.62% of the company’s stock.
• IQVIA exceeded quarterly expectations, reporting $3.15 in earnings per share and $4.37 billion in revenue, with revenue up 8.7% year over year. The company issued fiscal 2026 EPS guidance of $12.80–$13.00.
• The board authorized a $2 billion share-repurchase program, while analysts maintain a “Moderate Buy” consensus rating with an average price target of $241.88. Insiders, however, sold roughly $3.1 million of stock over the past quarter.

Rakuten Investment Management Inc. bought a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 27,459 shares of the medical research company's stock, valued at approximately $5,307,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. North Star Asset Management Inc. purchased a new position in IQVIA in the 2nd quarter valued at approximately $1,221,000. Empowered Funds LLC purchased a new stake in shares of IQVIA during the second quarter worth $3,210,000. United Capital Financial Advisors LLC acquired a new stake in shares of IQVIA in the second quarter valued at $1,567,000. Caitlin John LLC purchased a new position in IQVIA in the second quarter valued at $31,000. Finally, Equitable Holdings Inc. acquired a new position in IQVIA during the 2nd quarter worth $419,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares of the company's stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares in the company, valued at $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is owned by corporate insiders.

IQVIA Trading Down 0.7%

NYSE IQV opened at $260.48 on Friday. The firm's fifty day moving average price is $222.14 and its 200 day moving average price is $189.62. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $265.25. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The company has a market capitalization of $42.88 billion, a price-to-earnings ratio of 32.32, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA's quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

IQV has been the subject of several recent research reports. TD Cowen lifted their price objective on IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a research note on Wednesday, July 29th. HSBC restated a "buy" rating and set a $240.00 target price on shares of IQVIA in a research note on Monday, July 6th. Stifel Nicolaus lifted their price target on shares of IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Wall Street Zen cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $241.88.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.